Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Study to Evaluate ADI-002 in Hepatocellular Carcinoma and Other Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Clinical Study to Evaluate ADI-002 in Hepatocellular Carcinoma and Other Solid Tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 20 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADI-002 (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Adicet Bio

    • Most Recent Events

    • 12 Aug 2021 According to an Adicet Bio media release, the IND has been cleared and the trial is expect to initiate later this year.
    • 15 Sep 2020 According to an Adicet Bio media release, the company expects to file IND for ADI-002 GPC3 gamma-delta CAR-T as a near-term milestone.
    • 15 Sep 2020 According to an Adicet Bio media release, Adicet Bio today announced the completion of its previously announced merger with resTORbio, Inc. The new combined company will operate under the name Adicet Bio, Inc.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top